These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 35785030)

  • 1. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
    Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1
    Liu M; Wei F; Wang J; Yu W; Shen M; Liu T; Zhang D; Wang Y; Ren X; Sun Q
    Cell Death Dis; 2021 May; 12(5):465. PubMed ID: 33967272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
    Liang Y; Wang W; Zhu X; Yu M; Zhou C
    Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
    Koh V; Chakrabarti J; Torvund M; Steele N; Hawkins JA; Ito Y; Wang J; Helmrath MA; Merchant JL; Ahmed SA; Shabbir A; Yan So JB; Yong WP; Zavros Y
    Cancer Lett; 2021 Oct; 518():59-71. PubMed ID: 34126195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
    Xin B; Yang M; Wu P; Du L; Deng X; Hui E; Feng GS
    Hepatology; 2022 Sep; 76(3):630-645. PubMed ID: 34860431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
    Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
    Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
    Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
    Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
    Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
    JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC.
    Liu W; Zhang F; Quan B; Yao F; Chen R; Ren Z; Dong L; Yin X
    Cell Mol Gastroenterol Hepatol; 2024; 18(4):101377. PubMed ID: 38969205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
    Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
    Xin G; Chen Y; Topchyan P; Kasmani MY; Burns R; Volberding PJ; Wu X; Cohn A; Chen Y; Lin CW; Ho PC; Silverstein R; Dwinell MB; Cui W
    Cancer Immunol Res; 2021 Apr; 9(4):454-469. PubMed ID: 33579728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
    Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
    Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.